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tein values. We did not observe any correlation between
p16INK4a methylation and the initial characteristics of the
patients. However we observed almost the same differences in
OS and PFS as Mateos et al. did. Ng et al. reported similar inci-
dences of p16INK4a gene methylation in pre-treated and post-
treated MM patients.3 These findings suggest that in spite of
possible variations between techniques used, heterogeneity
of patients, and other unknown factors, p16INK4a methylation
analysis in MM might provide interesting prognostic informa-
tion and warrant future prospective studies.
The absence of prognostic impact of p15INK4b gene methy-
lation is in marked contrast with the prognostic value of
p16INK4a methylation. We previously reported frequent methy-
lation of p15INK4b and p16INK4a genes in CD138-purified plasma
cells from patients with monoclonal gammopathy of unde-
termined significance, suggesting that methylation of p15INK4b
and p16INK4a might be an early event in the course of MM.7
Combined with our current findings, these data suggest that
both p15INK4b and p16INK4a methylation might play a role in the
initial transformation of plasma cells. However, p15INK4b
methylation might exert a lesser influence on subsequent
tumor progression.
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Non-myeloablative stem cell transplantation with
low-dose total body irradiation and fludarabine for
metastatic renal cell carcinoma
We evaluated the feasibility of nonmyeloablative stem
cell transplantation for metastatic metastatic renal cell car-
cinoma after a non-myeloablative conditioning regimen
combining low-dose TBI and fludarabine. Seven consecutive
patients were included. Initial engraftment occurred in all
patients and 6/6 evaluable patients achieved sustained
donor chimerism. One patient experienced a partial response
but the other 6 progressed.
haematologica 2003; 88:
(http://www.www.haematologica.org/.htm)
Metastatic renal cell carcinoma (RCC) is largely insensitive
to chemotherapy. In 2000, Childs et al. published the results of
nonmyeloablative stem cell transplantation (NMSCT) combin-
ing cyclophosphamide and fludarabine in 19 patients with
metastatic RCC.1 Ten of the 19 patients enjoyed objective
responses, including 3 with sustained CR. Although the condi-
tioning regimen was nonmyeloablative, the neutrophil count
fell to less than 0.1×109/L in all patients.1 The Seattle team has
recently proposed an original approach to NMSCT with a con-
ditioning regimen based on 2 Gy TBI ± fludarabine, followed by
post-transplant immunosuppression with cyclosporine A (CyA)
and mycophenolate mofetil (MMF) that permitted to perform
the transplant in an ambulatory care setting.2 In the present
study, we report our experience with 7 patients with RCC.
Seven consecutive patients with metastatic RCC, were
included (Table 1). Written informed consent was obtained
from patients and donors and our institution’s Ethical Com-
mittee approved the protocol. Four patients had HLA-identi-
cal siblings and three had alternative donors. Conditioning
consisted in 90 mg/m2 fludarabine combined with 2 Gy TBI.2–4
The whole post-transplant procedure was carried out as out-
patient except in the haemodialyzed patient. Post-transplant
immunosuppression consisted in CyA and MMF.3 Disease
responses were defined using the criteria of Childs et al.1 Stem
cell mobilisation and collection were carried out as previous-
ly reported.5 The protocol involved a prospective comparison
of graft manipulation, so that patients #1-3 received unma-
nipulated PBSC, patients #4-6 CD8-depleted PBSC and patient
#7 CD34-selected PBSC.3 Three patients without GVHD
received additional DLI (per protocol) on days 40 and 80. Per
protocol, DLI were unmanipulated in patient 2 and  CD8-
depleted in patients #5 and 7. Chimerism6,8 was assessed as
previously reported.3
None of the patients developed grade >2 regimen-related
toxicity(7). The neutrophil nadir occurred on day 7 and was
0.97×109/L (0.12-1.67). Two patients did not require hospitali-
sation within the first 30 days following NMSCT, and the oth-
er five were hospitalised for a median of 9 (6-22) days. Total
white blood cell (WBC) and CD3+ cell chimerisms were 91%
(90-95) and 67% (20-89) on day 28 and 95 (95-96) and 83 (32-
96) on day 100, respectively (Figures 1A and 1B).
We observed only 1 partial response. This response occurred
in patient #1 who had extensive lung metastases. The disease
remained stable the first 150 days after transplantation (Figure
1C) but the tumor mass was markedly (> 50%) reduced on day
240. This patient experienced both acute and chronic GVHD.
Response persisted until day 389 when a chest CT-scan showed
elimination or major reduction of 80% of the metastases with
stabilisation of the others, with the exception of two lesions
that progressed (Figure 1D). Unfortunately the patient subse-
quently relapsed in the liver and died of disease progression. All
other patients progressed (Table 1). We show here that engraft-
ment can be achieved in RCC patients with this low-intensity
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Figure 1. Evolution of myeloid (A) and T-cell
(B) chimerism in the 5 RCC patients who
survived more than 50 days after the trans-
plant. (C-D) Chest CT scan in patient 1. The
disease remained stable the first 150 days
after transplantation (C) but the tumor
mass was markedly (>50%) reduced on day
240. Response persisted until day 389 (D)
with elimination or major reduction of 80%
of the metastases (large arrow) and stabi-
lization of the others, except two lesions
that progressed (one is pointed by the small
arrow).
Table 1. Patients, donors and clinical evolution.
Patients #1 #2 #3 #4 #5 #6 #7
Age/Sex 64/M 56/F 63/M 49/M 46/M 51/M 64/M
No of sites of metastases 2 4 2 5 4 2 3
Largest metastasis (cm) 3.6×3 2×2 2×2 15×6.5 5×5 15×4 5×5
Karnofsky’s score 100 80 80 70 80 50 80
Donor
Age/Sex 48/F 46/F 34/M 39/F 37/M 36/M 44/M
Relationship sibling sibling unrelated sibling sibling unrelated child
HLA compatibility HLAid HLAid HLAid HLAid HLAid HLAid 1 MM
Graft
PBSC manipulation None None None CD8- CD8- CD8- CD34-
depletion depletion depletion selection
No. of CD34+/kg infused (×106) 6.9 7.8 14.2 3.8 4.0 4.0 7.3
No. of CD3+/kg infused (×106) 382 360 370 206 80 105 0.08
No. of CD8+/kg infused (×106) 99 178 167 7 3 6 0.03
DLI : CD3+/kg infused (×106)
DLI #1 (day 40): 0 10 0 0 50 0 10
DLI #2 (day 80): 0 20 0 0 0 0 20
Graft versus-host disease 
Acute GVHD (grade) 2 0 2 0 0 0 3*
Chronic GVHD Extensive No No N/A N/A N/A No
Hospitalization in the first 30d
No. of days 6 13 0 9 7 22 0
Cause Fever Gastric – Dyspnea Sepsis Pain –
hemorrhage (progression) (progression)
Disease evolution
Best response achieved 75% PR None None None None None None
Current disease status Relapse PD PD PD PD PD PD
Survival 
Survival status (day) Death(763) Death(151) Alive(220+) Death(22) Death(93) Death(38) Death(120)
Cause of death PD PD - PD PD PD PD
M: male; F: female; HLAid: HLA identical; PR: partial response; PD: progressive disease; 1MM: one HLA mismatch; N/A: not applicable;
*after DLI: interferon-α therapy and CyA withdrawal.
regimen. Furthermore, we demonstrate for the first time that
alternative donors can be used successfully for this purpose.
Moreover, our results evidence that nearly full donor chimerism
can be achieved in the majority of RCC patients treated with
this approach, even in recipients of CD8-depleted or CD34-
selected PBSC.Patients included in our study experienced less
toxicity than patients reported by Childs et al.:1 the neutrophil
count fell below 0.5×109/L in 1/7 patients compared with 19/19
patients in the study of Child et al. and none of our patients
experienced grade >2 Bearman toxicities nor died of trans-
plant-related complications.
Although the primary aim of this pilot study was not to
assess the occurrence of a graft-versus-tumor effect but to
evaluate the feasibility of this low-intensity technique in the
RCC setting, we observed a response in 1 of 7 patients. Patient
1 achieved a partial response 8 months after the transplant in
the context of extensive chronic GVHD, demonstrating that
immune responses can be obtained after this low-intensity
NMSCT approach. However, as illustrated in patients #4-7,
this approach should not be offered to patients with very
advanced disease at time of transplant. The time necessary
for identifying a donor and organise the transplant, as well as
the delay between transplantation and any significant tumor
response, should restrict the applicability of this approach to
patients with less advanced disease.
In conclusion, our study showed the feasibility and low tox-
icity of NMSCT with 2 Gy TBI plus fludarabine for patients
with metastatic RCC. However, this investigational approach
should be carried out only in Centers with proven experience
in this field and within approved protocols. 
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Editorial note. The reader may be interested in articles on allo-
geneic hematopoietic cell transplantation for solid tumors that
appeared in a recentsupplement of this journal (9-18). This sup-
plement can be freely downloaded at the following web site:
http://www.haematologica.it/free/solidtumors.pdf.
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